Targets

Cereblon (CRBN)

21 articles

Computational & AIJournal of Chemical Theory and Computation

A restrained umbrella-sampling molecular dynamics protocol ranks molecular glue ternary complexes by stability and captures a key selectivity determinant that cheaper scoring methods miss

  • The authors built a molecular dynamics workflow that estimates ternary complex binding free energy by umbrella sampling along a geometric thermodynamic cycle, using conformational and orientational restraints to pull the complex apart.
  • It was tested retrospectively on interface point mutants of the CK1α–lenalidomide–CRBN complex, where predictions tracked experimental affinities closely, and on BRD4 degrader series engaging DCAF16, where the ranking agreed with biophysical assay trends.
  • The method explained BRD4 selectivity as dependent on one interfacial glycine, a result that faster MM/GBSA and HADDOCK scoring did not reproduce.
PointsBased on the abstract

Retrospective agreement on point mutants and two series is a low bar for a method this expensive: the question is whether it ranks within a congeneric glue series prospectively, where differences are small and cooperativity dominates. Umbrella sampling also hinges on the starting pose and restraint choices, so I'd want replicate runs and error bars. On my project I'd reserve it for a handful of shortlisted compounds, not triage.

Computational & AIJournal of Chemical Theory and Computation (ACS)

Umbrella-sampling free energies rank molecular glue ternary complexes

  • Molecular dynamics with umbrella sampling, run along a geometric thermodynamic cycle using conformational and orientational restraints, estimates how stable a glue-induced target–E3 ligase complex is.
  • Tested on CK1α–lenalidomide–CRBN interface mutants and on BRD4 degraders recruiting DCAF16.
  • Results tracked experimental affinities and biophysical trends, and explained BRD4 selectivity via one interfacial glycine, which MM/GBSA and HADDOCK scoring missed.
PointsBased on the abstract

Two E3 systems and a handful of mutants is a thin base for calling a protocol predictive, so I'd want a blind, prospective ranking on a chemotype it hasn't seen. Umbrella sampling per complex is also far costlier than MM/GBSA, and glue cooperativity depends on ternary-induced protein-protein contacts. On our own glue series, I'd first test whether it reproduces known SAR cliffs before spending GPU time.

Medicinal ChemistryEuropean Journal of Medicinal Chemistry (Elsevier)

First oral GLI1 PROTAC takes aim at colorectal cancer

  • Targets GLI1, the Hedgehog effector downstream of SMO, to reach tumors resistant to SMO inhibitors, using a new series of CRBN-recruiting PROTAC degraders.
  • Lead LRG20 degrades GLI1 and GLI2 more than GLI3 in HT-29 colorectal cells, via the ubiquitin-proteasome system, sparing typical CRBN neo-substrates.
  • It suppresses cell growth, shows oral exposure in vivo, and curbs HT-29 xenograft tumors without evident toxicity.
PointsBased on the abstract

A transcription factor with no pocket is a classic degrader use case, and sparing the usual CRBN neo-substrates is reassuring. But GLI1/GLI2 preference over GLI3 needs proteome-wide support, and I'd want a non-degrading CRBN-binder control to prove the effect isn't just pathway noise. Next check: activity in SMO-inhibitor-resistant models, plus ternary-complex cooperativity, since oral exposure for a large PROTAC is the real surprise.

Medicinal ChemistryEuropean Journal of Medicinal Chemistry

Entinostat-based PROTACs preferentially degrade HDAC3 in colorectal cancer models

  • Two PROTAC series were built on the HDAC inhibitor entinostat, recruiting either VHL or CRBN E3 ligases.
  • A representative from each series drove time-dependent HDAC loss, favouring HDAC3, followed by apoptosis and lower viability in colorectal cancer models.
  • Activity was tested in patient-derived organoids and a CAM model, with p21 and the stemness markers CD44 and LGR5 probing acetylation-driven gene regulation.
PointsBased on the abstract

Preferential HDAC3 loss may partly reflect the entinostat warhead's own isoform profile, so the first things to look for are a non-binding or inactive-epimer control and a way to separate degradation from inhibition, such as HDAC3 knockout or proteasome and neddylation blockade. A comparison with other HDAC3-selective PROTACs would also show whether the VHL versus CRBN choice shapes isoform bias.

Medicinal ChemistryBioorganic & Medicinal Chemistry

Cereblon molecular glues are widening their reach to protein kinases

  • This review covers cereblon-based molecular glue degraders that recruit protein kinases as neosubstrates, extending beyond classic IMiD targets.
  • Structures show kinases engaged through varied degron types, such as helical G-loops, an αC-helix glutamate and composite surfaces, explaining selectivity.
  • Degradation removes catalytic and non-catalytic functions, which may overcome inhibitor resistance and strengthen combinations.
PointsBased on the abstract

Whether glue-induced kinase degrons are structural motifs one can design toward, or quirks of individual scaffolds, is still open. Matched kinase inhibitors and ternary-complex data would help separate true degradation from inhibitor-driven effects. A useful next step is mapping which ligand edits move the exit vector toward the G-loop, then testing how far that logic generalizes across kinases.

Medicinal ChemistryACS Chemical Biology

Why BRD9 PROTACs underperform in mice, and a humanized-E3 fix

  • Widely used CRBN- and VHL-based BRD9 degraders such as dBRD9 and VZ185 are much less potent in mouse cells, even though BRD9 itself is highly conserved.
  • The gap points to species differences in the E3 ligases, notably the Crbn I391 residue and structural variation in VHL, which likely hamper ternary complex formation.
  • Expressing human CRBN or VHL, or introducing a CrbnI391V mutation, restored potency in mouse cells and improved BRD9 degradation in vivo.
PointsBased on the abstract

Anyone who has watched a PROTAC look great in human lines and flat in a mouse efficacy study will recognize this. It is a reminder that degrader PK/PD in rodents can fail for E3 reasons rather than compound reasons, so a CrbnI391V or humanized-E3 model is worth setting up early. It also argues for profiling ternary complex formation across species before reading a negative in vivo result as a dead series.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Much of the PROTAC target-engagement spread is exposure, not E3 recognition

  • Twenty PROTACs with varied E3 ligands, linkers and target binders were profiled in intracellular NanoBRET competition assays against cereblon and VHL tracers.
  • Apparent potency spread widely when referenced to applied concentration, and passive Caco-2 permeability explained little of it.
  • Correcting for measured intracellular unbound exposure shrank the spread dramatically, matching values from permeabilized cells.
PointsBased on the abstract

Before I read a PROTAC SAR table as E3 affinity, I'd now ask what the cell actually saw. If most of the shift is unbound exposure, linker tweaks that look like potency gains may just be permeability gains, and measuring exposure early keeps us from chasing the wrong variable.

Medicinal ChemistrybioRxiv

A covalent ligand at cereblon's cryptic Cys287 locks the E3 ligase open and blocks IMiD-driven degradation

  • Cysteine-directed chemoproteomic screening found covalent ligands for Cys287, an allosteric pocket far from the thalidomide-binding site.
  • Lead VVD-105917 broadly blocks degradation of neosubstrates driven by IMiDs and CELMoDs.
  • Cryo-EM shows it traps cereblon in its open, inactive state, and ligand order matters. A previously reported ligand at the same site promotes closure instead, so the pocket is 'sign-switchable'.
PointsBased on the abstract

Every CRBN drug so far sits in one orthosteric pocket, so a covalent handle that controls the open/closed switch is a genuinely new knob. A pan-inhibitor is an excellent tool to dissect degrader mechanisms and rescue off-target degradation. A site that can push either way also means a degrader-enhancing ligand might be hiding in the same pocket. This is a preprint, so wait for review.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Scaffold-hopped BCL6 PROTAC degrades its target in DLBCL cells and works orally in xenografts

  • Scaffold hopping from the BCL6 ligand BI-3802 gave a new tricyclic oxazinoquinolinone binder.
  • Linker and CRBN-recruiter tuning produced compound 15, a PROTAC that degraded BCL6 quickly and potently, in a CRBN- and proteasome-dependent way.
  • It strongly suppressed BCL6-dependent DLBCL cell growth, and oral dosing inhibited tumor growth in an OCI-LY1 xenograft without evident toxicity.
PointsBased on the abstract

BI-3802 is a polymerizing degrader with a peculiar mechanism, so a conventional CRBN-recruiting PROTAC from a fresh tricyclic core is a useful alternative route to BCL6 removal. Oral efficacy matters most here; I'd want to see how the molecule balances size and permeability, and whether degradation depth tracks with tumor response across non-OCI-LY1 lines.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Isoform-selective ULK1 PROTAC gives longer autophagy suppression than an inhibitor

  • ATP-competitive inhibitors struggle to separate ULK1 from the near-identical ULK2, so the authors built cereblon-recruiting degraders instead.
  • Structure-guided optimization gave MR-9036, which degrades ULK1 without touching ULK2 or IMiD neo-substrates, with ternary complex formation and proteasome dependence confirmed.
  • After compound washout it kept autophagy suppressed longer than the clinical ULK1/2 inhibitor DCC-3116, with antitumor activity in KRAS G12C NSCLC models.
PointsBased on the abstract

Selectivity between paralogs is where degraders can beat occupancy-driven drugs, and this is a clean example. What I'd check next is whether ULK2 compensation shows up in vivo, and whether washout durability holds in a model with realistic drug exposure rather than a pulse.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

One atom flips a CRBN degrader from NSD2-selective to GSPT1-selective

  • Starting from LLC0424, an NSD2 degrader that also engages GSPT1, a single-atom change gave two close analogues: 424-ND (NSD2-selective) and 424-GD (GSPT1-selective).
  • 424-ND suppressed androgen receptor signaling in prostate cancer cells, while 424-GD triggered the integrated stress response.
  • Biolayer interferometry showed distinct ternary-complex cooperativity for each target, and simulations suggested different low-energy conformations explain the bias.
PointsBased on the abstract

Degrader selectivity here tracks ternary-complex cooperativity, not binary affinity, which is exactly what I'd want to see in an SAR table. A matched pair this tight is a ready-made probe set for NSD2 and GSPT1. I'd check proteome-wide selectivity and whether the cooperativity trend holds in cells.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Oral isoindolinone GSPT1 glue degrader LG-NE-29 targets glioblastoma models

  • A viability-based phenotypic screen flagged GSPT1 as a vulnerability in glioblastoma cells, where resistance to temozolomide arises quickly.
  • Optimizing an isoindolinone series for metabolic stability gave LG-NE-29, a molecular glue that drives CRBN-dependent ubiquitination and proteasomal degradation of GSPT1.
  • It is reported to avoid the metabolic weaknesses of earlier scaffolds, and to be orally bioavailable with activity in glioblastoma xenograft models.
PointsBased on the abstract

Isoindolinone CRBN glues usually die on metabolism, so fixing that liability is the real story here. Before I believe it, I'd want the GSPT1 DC50/Dmax, proteome-wide selectivity (IKZF1/3, other neosubstrates), and oral PK with brain exposure. GSPT1 degradation is also broadly cytotoxic, so the therapeutic window in normal cells matters.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

A '2-in-1' PROTAC Folds the Cereblon Ligand into the HDAC8 Cap to Shrink the Degrader

  • Instead of tethering two ligands, the cereblon-binding motif is built into the capping group of an HDAC8 inhibitor, so one structural element engages both proteins.
  • Versus the group's first-generation degrader, the compact analogs are smaller, more selective and more drug-like.
  • They degrade HDAC8 potently in vivo.
PointsBased on the abstract

Most of us accept PROTAC bulk as a tax; fusing the E3 ligand into the warhead's cap group attacks that directly and is a transferable idea for other zinc-enzyme targets. The question I'd press is whether the shared motif compromises either binding event or cereblon neosubstrate selectivity. If in vivo degradation holds with better properties, the 'linkerless' direction deserves more attention.

Medicinal ChemistryAngewandte Chemie International Edition (Wiley)

Three Chemoselective Routes Turn Cereblon PROTACs into Cleavable Prodrugs

  • Cereblon-recruiting PROTACs are hard to derivatize for prodrug delivery; the paper offers three orthogonal handles: triazole quaternization, tertiary-amine alkylation and a hydroxyl linker.
  • The approaches give cleavable prodrugs with tunable release kinetics, compatible with PEGylated constructs and bottlebrush prodrugs.
  • Representative examples showed controlled degrader release, in vitro anticancer activity, tumor accumulation and preliminary in vivo efficacy.
PointsBased on the abstract

The real PROTAC problem is exposure rather than ternary-complex cooperativity, so a modular way to mask and release them is overdue. Chemoselectivity on a glutarimide-bearing molecule is the practical point: if it works on existing degraders without re-optimization, it is genuinely reusable. I'd check release in plasma versus tumor, and whether the masked forms avoid premature cereblon engagement.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

CRBN-Based Degrader Removes PTP1B and TCPTP to Reawaken Anti-Tumor T Cells

  • Scientists converted an F2Pmp-based dual PTP1B/TCPTP inhibitor into a CRBN-recruiting bifunctional degrader, named X1.
  • X1 shows improved potency, selectivity, and plasma exposure after intraperitoneal dosing versus earlier tools.
  • Degrading both phosphatases boosts TCR signaling in T cells and IFNγ-driven JAK/STAT1 signaling in tumor cells, raising MHC-I antigen presentation.
  • In a mouse tumor model, X1 alone or with anti-PD-1 increased T cell infiltration/activation and drove robust anti-tumor efficacy.
PointsBased on the abstract

F2Pmp warheads are notoriously charged and permeability-poor, so seeing real plasma exposure after IP dosing of a CRBN degrader built on one is the actual win here — event-driven pharmacology bailing out a classically undruggable phosphotyrosine mimetic. Also curious whether ternary-complex formation buys any PTP1B/TCPTP discrimination beyond what the near-identical catalytic sites let the warhead alone achieve.

Medicinal ChemistryAngewandte Chemie International Edition (Wiley)

New Molecular Glue Degrader Targets WBP4, Debuts wTAG Degron-Tag Platform

  • WBP4, a spliceosome-associated scaffold protein long considered undruggable, now has a first-in-class molecular glue degrader: dWBP4-1, which selectively eliminates it.
  • The compound works through the CRBN E3 ligase, engaging WBP4 via a canonical G-loop interface to trigger rapid, highly potent degradation.
  • Proteome-wide profiling showed the degrader was highly selective, with minimal off-target effects on gene expression or splicing patterns.
  • The team pinpointed a compact 41-amino-acid region of WBP4 sufficient to serve as a degradation tag, naming the resulting chemical-genetic system "wTAG."
  • When attached to other proteins of interest, wTAG enabled clean, dose-dependent degradation without the "hook effect" that limits many degrader tools, expanding its potential as a general research platform.
PointsBased on the abstract

WBP4 is a spliceosome scaffold with no ligandable pocket — this isn't a kinase-with-a-degron-tail story, it's proof CRBN can be steered onto a genuinely undruggable surface via a G-loop contact. That binding hypothesis is worth stealing for other scaffold targets sitting in my own tractability triage pile. The selectivity data is the real flex: clean proteome-wide profile AND minimal splicing perturbation, exactly where glues usually get you in trouble (neosubstrate promiscuity, cryptic RBM39-style splicing hits). Getting both together is rare. wTAG might matter more than the degrader itself — a 41-residue portable degron with no hook effect is a cleaner dTAG-class tool, and I'd rather have that in my assay toolbox than another single-target lead.

Medicinal ChemistryAngewandte Chemie International Edition (Wiley)

First-in-Class Molecular Glue Selectively Degrades Spliceosome Protein WBP4 via CRBN

  • Discovered dWBP4-1 through proteomic profiling of a CRBN-binding compound library, followed by SAR optimization.
  • Acts as a molecular glue, forming a CRBN ternary complex via a canonical G-loop-mediated interaction to recruit WBP4 (WW domain-binding protein 4), a spliceosome-associated scaffold protein.
  • Degradation is rapid and occurs at nanomolar concentrations.
  • Selectivity across the proteome is reported as high, with minimal downstream transcriptomic or alternative-splicing effects observed elsewhere.
  • Mapped a minimal ~41-residue WBP4 degron sequence and used it to build "wTAG," a fusion-tag degradation platform.
  • wTAG enables monotonic, dose-dependent degradation without the hook effect seen in some bifunctional degraders.
PointsBased on the abstract

A canonical G-loop-mediated ternary complex — reassuring, not exotic: this is the same validated CRBN surface, not a new liability profile to characterize from scratch. The compact ~41-residue degron is the real tell for tractability — that's a defined element, not a diffuse IDR, so SAR here should be rational rather than lucky. Nanomolar potency with reported high proteome-wide selectivity is the headline number, though for a spliceosome-associated protein I'd want orthogonal splicing/transcriptomic data before fully trusting "minimal downstream effects." The piece I'd actually chase into my own work is wTAG: a monovalent, hook-effect-free degron tag beats dTAG-style bifunctional systems for clean dose-response in target-validation studies, regardless of whether WBP4 itself ever becomes a drug target.

Medicinal ChemistryNature Communications (Nature)

AI-Guided Path to VAV1-Targeting Molecular Glues

  • VAV1 is a hematopoietic-restricted signaling protein of interest in blood cancers and autoimmune conditions, prompting efforts to target it via induced protein degradation.
  • High-throughput, unbiased global proteomics screening identified phenyl-glutarimide degrader compounds that recruit CRBN to selectively degrade VAV1.
  • VAV1's C-terminal SH3-2 domain proved essential for ternary complex formation, and structural work uncovered a novel "RT-loop" degron there—distinct from the "G-loop" degrons used by other CRBN glues—validated by mutagenesis.
  • An AI-based protein structure-prediction workflow modeled the ternary complex to support this mechanistic finding.
  • Free energy perturbation calculations on the predicted structures generated cooperativity scores that correlated with experimental potency, demonstrating a computational strategy to prioritize and optimize molecular glue analogs faster than empirical screening alone.
PointsBased on the abstract

The real headline isn't the molecule, it's the RT-loop degron. G-loop CRBN neosubstrates have basically been the only playbook since the IMiD era, so a structurally distinct degron sitting in VAV1's SH3-2 domain is a genuine expansion of the addressable degradable proteome, not just one more target on the pile. The phenyl-glutarimide warhead itself is bog-standard IMiD-adjacent chemistry — nothing novel there; the real innovation is in the target-engagement biology, not the medchem. VAV1's hematopoietic-restricted expression is a nice built-in selectivity advantage most degrader programs would kill for. On the FEP/AI ternary angle: cooperativity scores tracking potency across one series is promising, but it's one dataset — I'd want to see it prospectively rank blind analogs before I trust it over empirical SAR.

Medicinal ChemistryNature (Springer Nature)

TRI-611: A Brain-Penetrant Molecular Glue Takes Aim at ALK-Driven Lung Cancer

  • TRI-611 is an orally dosed molecular glue degrader designed to eliminate ALK fusion proteins that drive a subset of non-small cell lung cancers.
  • Rather than blocking ALK's active site like conventional inhibitors, it recruits the E3 ligase adaptor cereblon to a distinct surface on ALK, forming a complex that tags the protein for degradation.
  • The molecule is reported to be highly selective, sparing other cereblon-dependent targets and unrelated kinases, and it degrades both wild-type and kinase-inhibitor-resistant ALK fusion variants.
  • A central finding is brain penetrance: TRI-611 produced tumor regressions in intracranial as well as subcutaneous models, addressing CNS metastases that limit many existing ALK-targeted therapies.
  • Degradation was rapid and long-lasting, and combining TRI-611 with standard ALK inhibitors produced more durable responses in preclinical models.
PointsBased on the abstract

TRI-611 recruiting cereblon to a distinct, non-canonical surface on ALK — rather than working off the usual IMiD-derived degron — is the real chemistry story here; if that ternary interface holds up, it's a fresh template for kinases that don't glue easily. Wiping out kinase-inhibitor-resistant fusion variants is the killer selling point: degradation doesn't care about the affinity losses that gatekeeper/compound mutations inflict on ATP-competitive binders, so a mutant that's dead to a TKI can still form a productive ternary complex. Getting CNS exposure out of a CRBN glue is the harder chemical win — these scaffolds usually sit well outside Ro5, so brain penetrance without sacrificing ternary complex cooperativity argues for real optimization, not luck. Selectivity over other CRBN neosubstrates plus the TKI-combo data suggest this could slot in alongside inhibitors rather than just after them.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

One Molecule, Two Jobs: A Compact PROTAC Strategy for Degrading HDAC8

  • Researchers describe a "2-in-1" PROTAC design that merges the CRBN-recruiting ligand into the capping group of an HDAC8 warhead, rather than linking two separate ligands.
  • This lets one structural motif engage both HDAC8 and the CRBN E3 ligase, unlike conventional heterobifunctional PROTACs, whose separate POI- and E3-binding units plus linker often yield large, poorly drug-like molecules.
  • Relative to the team's earlier HDAC8 degrader YX862, the new compact degraders show improved selectivity, lower molecular weight, and better overall drug-like properties.
  • The compounds also achieved effective HDAC8 degradation in vivo, indicating therapeutic potential beyond cell-based activity.
  • The study proposes a broader design framework for building smaller, more efficient PROTACs by integrating target engagement and E3 ligase recruitment into a single motif.
PointsBased on the abstract

The move that catches my eye: folding the CRBN ligand into the HDAC8 warhead's capping group instead of bolting on a full separate E3 unit plus linker. That's a direct attack on the MW/logP bloat that tanks oral exposure in most heterobifunctional degraders — not incremental linker trimming, a structural collapse of the whole ternary-complex scaffold. Going from YX862 to these analogs with better selectivity AND lower MW (rarely a package deal) says the capping vector is actively shaping the HDAC8–CRBN interface, not just shedding atoms. In vivo degradation data is the sanity check I always want before trusting a compact-PROTAC claim. I'd want SAR around that fused cap next — how much substituent tolerance before CRBN engagement drops off. Feels like a real template for smaller, more drug-like degraders, not just this target.

Medicinal ChemistryJournal of the American Chemical Society (ACS)

Modified Thalidomide Selectively Degrades an 'Undruggable' Transcription Factor

  • Researchers report that 5-tBu-thalidomide, a chemically modified thalidomide analog, acts as a molecular glue that recruits the CRBN E3 ligase to drive potent, selective breakdown of FIZ1, a zinc-finger transcription factor linked to FLT3 signaling.
  • FIZ1 contains eleven zinc-finger domains, several of which carry the degron sequence normally required for thalidomide-class drugs to engage, yet the compound acts almost exclusively through a single finger, zinc finger 8.
  • Computational modeling of the CRBN–drug–FIZ1 ternary complex reveals the contacts that favor this domain over the others, explaining the selectivity.
  • The work offers a template for rationally designing thalidomide-based glues that target individual zinc fingers within otherwise 'undruggable' transcription factors.
PointsBased on the abstract

A single tert-butyl group turning thalidomide into a ZF8-selective glue is the kind of result that makes you go back and stare at your own IMiD SAR data — this is minimal medicinal chemistry, not a redesigned scaffold, and that's the exciting part. The real puzzle is why one finger out of eleven degron-competent copies wins. If the ternary-complex modeling holds up, this is a rare case where computation actually explains selectivity instead of rationalizing it after the fact. IMiD-class glues have a promiscuity problem — off-target zinc fingers are exactly how thalidomide's teratogenicity got explained via SALL4. A route to finger-specific engagement is the fix chemists have wanted since that story broke. I'd want a neosubstrate panel run immediately: does 5-tBu still hit SALL4/IKZF1/GSPT1, or did this substitution buy clean selectivity for free? That answer decides whether this is a platform or a one-off.